Caribou Biosciences, Inc. (CRBU) climbed 3.34% to $2.5010, up $0.0810, following the release of positive clinical data from both its ANTLER and CaMMouflage Phase 1 trials.
The company announced that its allogeneic anti-CD19 CAR-T therapy (vispa-cel/CB-010) achieved an 82 percent overall response rate (ORR) and 64 percent complete response (CR) rate in the 22-patient confirmatory cohort of the ANTLER trial.
Additionally, its allogeneic anti-BCMA CAR-T therapy (CB-011) in the CaMMouflage trial delivered an ORR of 92 percent, CR/sCR rate of 75 percent, and MRD negativity of 91 percent (in 11/12 evaluable BCMA-naïve patients) at the recommended dose for expansion.
Caribou said it will initiate the dose expansion of CB-011 before year-end and plans to design a pivotal Phase 3 trial for vispa-cel in 2L LBCL patients in alignment with the U.S. Food & Drug Administration.
On the day of the news, CRBU opened near $2.45, reached a high of $2.60, and a low of $2.40, compared to the previous close of $2.4200. Trading volume surged significantly (exact volume data pending) versus its average, reflecting heightened investor interest. The stock's 52-week range is approximately $1.20 - $3.50.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.